FDA IND application for ST-01156 Ph 1 trial in patients with advanced solid tumor and heme malignances August 19, 2025
RP2D in Ph 1 Study of SENTI-202 for the Treatment of R/R Heme Malignancies, Including AML, Determined August 12, 2025
Updated BEXMAB data in frontline HR-MDS shows complete remission rate substantially increased to 43% August 11, 2025
ViroCell Biologics and AvenCell Therapeutics to accelerate development of novel allogeneic CAR-T therapies for blood cancers August 5, 2025
CBX-663 nominated for the treatment of a broad range of solid tumor and heme malignancies July 29, 2025
Xenetic Biosciences Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform July 29, 2025
Dose Level 1 of ANGELICA TRIAL completed; Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Heme Malignancies July 23, 2025
FDA approves label updates for Breyanzi and Abecma to reduce certain patient monitoring requirements and removes the Risk Evaluation and Mitigation Strategy (REMS) programs July 1, 2025
Sarah Cannon Research Institute Announces Strategic Alliance with AbbVie to Advance Novel Cancer Therapies June 3, 2025
Lumanity and Parker Institute for Cancer Immunotherapy (PICI) Announce Partnership to Accelerate Immunotherapy Innovation June 3, 2025
Orionis Biosciences and Genentech to Discover and Develop Molecular Glue Class Medicines for Cancer May 27, 2025
Tempus Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline May 21, 2025
AbbVie and ADARx Pharmaceuticals to Develop Next-Gen siRNA Therapies Across Multiple Therapeutic Areas May 21, 2025
Tempus Enters Multi-Year Strategic Collaboration with Boehringer Ingelheim to Advance its Cancer Pipeline May 21, 2025
GTB-3650 Ph 1 Trial Advanced to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals May 21, 2025
FDA lifts the clinical hold on IND applications for the EBVALLO™ (tabelecleucel) program May 13, 2025
Strategic Pipeline Prioritization Announced with Focus on CB-010 and CB-011 Oncology Programs April 30, 2025
